Investigational Combination Therapy Shows Promising Results in Specific Melanoma Patients
News
Melanoma patients with BRAF mutations may benefit more from the combination of encorafenib and binimetinib, two investigational medicines, than from Zelboraf (vemurafenib) monotherapy, according to data from the first part ... Read more